Name: Sorafenib
Price: 180.00 USD

- Overview
  - Please contact us at for specific academic pricing.
    
    Background
    
    Sorafenib is an oral multikinase inhibitor with activity against Raf kinase and several receptor tyrosine kinases, including vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor (PDGFR), FLT3, Ret, and c-Kit. sorafenib, inhibits tumor growth and disrupts tumor microvasculature through antiproliferative, antiangiogenic, and/or proapoptotic effects. sorafenib blocks Raf kinase signaling, inhibits tumor cell proliferation, and induces apoptosis in vitro. In addition, sorafenib exhibits robust antitumor efficacy.
- Properties
  - Alternative Name
    
    BAY-43-9006, Sorafenib, Nexavar, sorafenibum; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide
    
    CAS Number
    
    284461-73-0
    
    Molecular Formula
    
    C21H16ClF3N4O3
    
    Molecular Weight
    
    464.82
    
    Appearance
    
    A solid
    
    Purity
    
    99.89%
    
    Solubility
    
    ≥23.25 mg/mL in DMSO; insoluble in H2O; insoluble in EtOH
    
    Storage
    
    Store at -20°C
    
    * For Research Use Only
- Reference
  - 1. CHONG ZHANG, LIN‑WEN WU, et al. "DYRK1A suppression attenuates HIF‑1α accumulation and enhances the anti‑liver cancer effects of regorafenib and sorafenib under hypoxic conditions." Int J Oncol. 2022 Apr;60(4):45. PMID: 35244188
    2. Zhou Yu, Jiaying Du, et al. "LT-171-861, a novel FLT3 inhibitor, shows excellent preclinical efficacy for the treatment of FLT3 mutant acute myeloid leukemia." Theranostics. 2021 Jan 1;11(1):93-106. PMID: 33391463
    3. Qi Wang, Yaxun Guo, et al. "RNA binding protein DAZAP1 promotes HCC progression and regulates ferroptosis by interacting with SLC7A11 mRNA." Exp Cell Res. 2021 Feb 1;399(1):112453. PMID: 33358859
    4. Bai J, Liu Z, et al. "Mitochondrial metabolic study guided by proteomics analysis in hepatocellular carcinoma cells surviving long-term incubation with the highest dose of sorafenib." Aging (Albany NY), 11 (24), 12452-12475 2019 Dec 26. PMID: 31881007
    5. Cheriyan VT, Alsaab H, et al. "A CARP-1 functional mimetic compound is synergistic with BRAF-targeting in non-small cell lung cancers." Oncotarget. 2018 Jul 3;9(51):29680-29697. PMID: 30038713
    6. Sieber J, Wieder N, et al. "GDC-0879, a BRAF(V600E) Inhibitor, Protects Kidney Podocytes from Death." Cell Chem Biol. 2017 Dec 6. PMID: 29249695